The FTD-ALS Spectrum represents a clinical, genetic, and pathological continuum between Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). This overlap syndrome reflects the shared underlying biology of TDP-43 proteinopathy and common genetic determinants, particularly hexanucleotide repeat expansions in the C9orf72 gene. Patients may present with features of either condition, or develop both syndromes sequentially, with approximately 15% of ALS patients meeting criteria for FTD and up to 50% exhibiting subclinical cognitive or behavioral changes[1][2]^.
The spectrum encompasses a continuum from pure behavioral variant FTD (bvFTD) or ALS to the combined syndrome where patients manifest characteristics of both conditions. This overlap has significant implications for diagnosis, treatment strategies, and clinical trial design[3].
¶ Prevalence and Incidence
- ALS incidence: 1-2 per 100,000 person-years globally
- FTD incidence: 4-15 per 100,000 persons aged 45-64 years
- FTD-ALS overlap: 5-15% of ALS patients have comorbid FTD
- Gender distribution: Male predominance (1.3-1.5:1 for ALS; 1:1 for FTD)
- Age of onset: Typically 50-65 years for both conditions
Population-based studies show that the FTD-ALS spectrum accounts for a substantial proportion of both FTD and ALS cases, with the greatest overlap observed in patients with the C9orf72 hexanucleotide repeat expansion[4].
| Gene |
Location |
Protein Function |
FTD-ALS Association |
| C9orf72 |
9p21 |
DENN domain protein, Rab guanine nucleotide exchange |
Most common cause of familial FTD-ALS (30-40%) |
| TARDBP |
1p36 |
TDP-43 RNA-binding protein |
3-5% of familial ALS, rare FTD |
| FUS |
16p11 |
Fused in sarcoma, RNA-binding protein |
3-5% of familial ALS, rare FTD |
| GRN |
17q21 |
Progranulin, secreted growth factor |
~20% of familial FTD, rare ALS |
| MAPT |
17q21 |
Tau microtubule stabilization |
FTDP-17, rare ALS overlap |
| TBK1 |
12p13 |
TANK-binding kinase 1 |
Autophagy/mitophagy regulation |
The most significant genetic link in the FTD-ALS spectrum is the hexanucleotide repeat expansion in the first intron of C9orf72[5]:
- Normal repeats: <30
- Pathological repeats: >30 (typically 60-1000)
- Penetrance: Age-dependent, with most carriers developing symptoms by age 80
- Mechanisms: Three proposed pathogenic mechanisms:
- RNA toxicity: Repeat-expanded RNA forms nuclear foci that sequester RNA-binding proteins
- Dipeptide repeat (DPR) proteins: Translation of repeat RNA produces toxic DPRs (GA, GP, PA, PR, GR)
- Reduced expression: Repeat expansion leads to reduced C9orf72 mRNA and protein levels
TARDBP encodes TDP-43, the major protein accumulating in ALS and most FTD subtypes[6]:
- Over 50 pathogenic mutations identified, predominantly in the C-terminal glycine-rich domain
- Mutations cause TDP-43 mislocalization from nucleus to cytoplasm
- Leads to cytoplasmic aggregation and loss of nuclear function
- Both ALS and FTD cases show TDP-43 pathology (type B for ALS, type A for bvFTD)
FUS (Fused in Sarcoma) is an RNA-binding protein with prion-like properties[7]:
- Mutations account for ~3-5% of familial ALS
- Rarely associated with FTD
- FUS pathology characterized by basophilic inclusions
- Earlier age of onset compared to other ALS genetic subtypes
The hallmark pathological feature of FTD-ALS is the accumulation of phosphorylated TDP-43 in neurons[8]:
TDP-43 Pathology Classification:
├── ALS: Type B (skeletal muscle, motor neurons, spinal cord)
│ └── Cytoplasmic inclusions, loss of nuclear TDP-43
├── bvFTD: Type A (frontal cortex)
│ └── Short dystrophic neurites, neuronal perikarya
└── ALS-FTD: Combined patterns
└── Overlapping features
TDP-43 is a 414-amino acid nuclear protein that functions in:
- RNA splicing and stability
- mRNA transport
- MicroRNA biogenesis
- Stress granule formation
In FTD-ALS, TDP-43 undergoes:
- Hyperphosphorylation
- C-terminal truncation
- Ubiquitination
- Mislocalization to cytoplasm
- Formation of insoluble aggregates
| Protein |
FTD Subtype |
ALS |
FTD-ALS |
| TDP-43 |
Type A/B |
+++ |
+++ |
| FUS |
Type E (rare) |
+ |
+ |
| Tau |
Type D (rare) |
- |
- |
| α-Synuclein |
- |
+ |
+ |
RNA dysregulation is central to FTD-ALS pathogenesis:
- RNA foci formation: C9orf72 repeat-expanded RNA forms nuclear RNA foci that sequester RBPs (hnRNPA1, hnRNPA2B1, Pur-α)
- Splicing defects: TDP-43 loss-of-function causes aberrant splicing of thousands of neuronal transcripts
- Transport deficits: Impaired axonal mRNA transport contributes to neurodegeneration
- MicroRNA dysregulation: Altered miRNA profiles in ALS and FTD
C9orf72 repeat expansions cause nucleocytoplasmic transport dysfunction:
Repeat Expansion → RNA Foci → RBP Sequestration
↓
Importin/Exportin Dysregulation
↓
Nuclear Pore Complex Stress
↓
Impaired Nuclear Import/Export
↓
TDP-43 Mislocalization
Microglial activation and neuroinflammation are prominent in FTD-ALS:
- Increased TREM2 expression in microglia
- Complement system activation (C1q, C3)
- Pro-inflammatory cytokine elevation (IL-6, TNF-α)
- Astrocyte reactivity (A1 phenotype)
- The C9orf72 expansion itself may modulate microglial function through the innate immune system
The clinical spectrum encompasses multiple phenotypes:
- Progressive muscle weakness and atrophy
- Bulbar dysfunction (dysarthria, dysphagia)
- Behavioral changes (disinhibition, apathy)
- Executive dysfunction
- Mean survival: 2-3 years from symptom onset
- Behavioral variant FTD presentation
- Subsequent development of muscle weakness
- Less aggressive progression than pure ALS
- Survival: 5-10 years from symptom onset
- Initial bulbar presentation (dysarthria, dysphagia)
- Later cognitive/behavioral changes
- Often associated with C9orf72 expansion
- Asymmetric rigidity
- Apraxia
- Myoclonus
- Progressive motor decline
- Presence of progressive motor decline
- Evidence of upper and/or lower motor neuron signs in at least one region
- Electrophysiological evidence of denervation
- Core diagnostic features:
- Insidious onset
- Gradual progression
- Early loss of social conduct
- Early loss of insight
- Early signs of disinhibition
- Early apathy or loss of empathy
- Early loss of planning/judgment
- Meet criteria for both ALS and FTD, OR
- Have ALS with cognitive/behavioral impairment meeting at least 2 FTD criteria, OR
- Have FTD with emergent motor neuron signs
¶ Cognitive and Behavioral Profile
| Domain |
FTD-ALS |
Pure ALS |
Pure FTD |
| Executive function |
+++ |
++ |
+++ |
| Language |
++ |
+ |
+++ |
| Memory |
+ |
++ |
++ |
| Visuospatial |
+ |
+ |
+ |
| Behavior |
+++ |
+ |
+++ |
| Social cognition |
+++ |
+ |
+++ |
¶ Diagnosis and Biomarkers
MRI findings in FTD-ALS:
- Frontotemporal atrophy (especially poles and insula)
- Motor cortex atrophy
- Posterior frontal lobe asymmetry
- DTI: Reduced fractional anisotropy in frontal and motor tracts
- MRS: Elevated choline/creatine ratio in motor cortex
- EMG: Denervation potentials, fibrillation signs
- NCS: Often normal in pure ALS
- Transcranial magnetic stimulation: Reduced cortical excitability
| Biomarker |
FTD-ALS |
Clinical Utility |
| NfL (neurofilament light) |
Elevated |
Disease progression |
| pNfH (phosphorylated neurofilament heavy) |
Elevated |
Diagnostic specificity |
| TDP-43 (CSF) |
Elevated |
Disease activity |
| Progranulin (plasma) |
Reduced in GRN carriers |
Genetic screening |
| C9orf72 DPR (CSF) |
Elevated |
Disease-specific |
- C9orf72 hexanucleotide repeat analysis (standard of care)
- TARDBP sequencing
- FUS sequencing
- GRN sequencing (if progranulin low)
- MAPT sequencing (if FTDP-17 suspected)
- Primary FDA-approved ALS therapy
- 50mg twice daily
- Modulates glutamate transmission
- Small survival benefit (~2-3 months)
- Free radical scavenger
- IV infusion for 10 days monthly
- Indicated for early-stage ALS
- Modest functional benefit
For FTD-ALS patients:
- Acetylcholinesterase inhibitors: Avoid (may worsen behavioral symptoms)
- Memantine: Not recommended
- SSRIs: For behavioral symptoms (e.g., sertraline, citalopram)
- Antipsychotics: For severe agitation (use cautiously due to fall risk)
- Weight monitoring (weekly)
- Early PEG placement recommended
- High-calorie supplements
- Hydration management
- Pulmonary function monitoring (FVC, MIP)
- Non-invasive ventilation
- Cough assist devices
- Secretion management
- Neurology: Coordinate care
- Pulmonology: Respiratory management
- Gastroenterology: Nutrition support
- Psychiatry: Behavioral management
- Physical therapy: Mobility support
- Occupational therapy: ADL preservation
- Speech pathology: Communication support
- Social work: Caregiver support
| Target |
Approach |
Stage |
| C9orf72 |
Antisense oligonucleotides |
Phase 1-2 |
| SOD1 |
Tofersen (ASO) |
Approved |
| TARDBP |
Gene therapy |
Preclinical |
| FUS |
Gene therapy |
Preclinical |
| TDP-43 |
Small molecules |
Discovery |
- Mesenchymal stem cells (Phase 2-3)
- Neural stem cells (Phase 1)
Active and recent trials in FTD-ALS:
- NCT03098597: Tofersen for SOD1-ALS (completed, positive)
- NCT05055052: C9orf72 ASO (Phase 1/2)
- NCT05637863: Rapamycin for FTD-ALS (Phase 2)
- NCT05887308: Gene therapy for FUS-ALS (Phase 1)
¶ Disease Progression and Prognosis
| Parameter |
FTD-ALS |
Pure ALS |
Pure FTD |
| Age of onset |
55-65 |
55-65 |
55-75 |
| Duration (ALS) |
2-3 years |
2-4 years |
7-10 years |
| Duration (FTD) |
Ongoing |
- |
7-10 years |
| Cause of death |
Respiratory failure |
Respiratory failure |
Complications |
Negative prognostic factors:
- Age >60 at onset
- Bulbar onset
- Rapid progression
- Early cognitive/behavioral impairment
- Low baseline FVC
- Weight loss >10% at baseline
- C9orf72 expansion (for ALS component)
Neutral factors:
- Limb onset
- Male sex
- Early nutritional support
- Mouse: BAC transgenic models with human C9orf72 and expanded repeats
- Drosophila: Drosophila models showing DPR toxicity
- iPSC-derived neurons: Patient-derived neurons demonstrating RNA foci and DPR production
- Transgenic mice: TDP-43 A315T, M337V mutations
- Conditional models: Inducible TDP-43 expression
- Biomarker development: Blood-based NfL, pNfH for disease monitoring
- Gene therapy: Antisense oligonucleotides for C9orf72, TARDBP, FUS
- Targeted protein degradation: AUTOTAC, PROTAC approaches for TDP-43
- Immunotherapy: TDP-43 vaccination strategies
- Regenerative approaches: Stem cell replacement
- Earlier diagnosis
- Disease-modifying therapies
- Better biomarkers for clinical trials
- Understanding of phenotypic modifiers
- Integration of FTD and ALS clinical trial designs
The FTD-ALS spectrum connects to AD through:
- Shared TDP-43 pathology in ~30% of AD cases
- Common genetic risk factors (APOE)
- Overlapping behavioral phenotypes
- Microglial activation patterns
The intersection of TDP-43 pathology in AD (termed "limbic-predominant age-related TDP-43 encephalopathy" or LATE) represents a key link between proteinopathies[1]. Recent studies demonstrate that TDP-43 pathology in AD follows a predictable staging pattern, beginning in the amygdala and spreading to the hippocampus and neocortex, similar to the progression of tau pathology[2].
Key molecular intersections include:
- Mitochondrial dysfunction: Both conditions show impaired complex I activity and reduced ATP production
- Autophagy-lysosomal pathway: VPS35, GRN, and other genes implicated in both conditions
- Neuroinflammation: Shared microglial activation patterns with TREM2, CD33, and PLD3 as common risk factors
- RNA metabolism: Common defects in splicing and RNA transport
- C9orf72 expansion in some PD cases (~3-5% of PD with dementia)
- α-Synuclein pathology in ~5% of ALS-FTD
- Shared mitochondrial dysfunction through PINK1/Parkin pathway
- Overlapping therapeutic targets ( autophagy enhancers, mitochondrial protectors)
The relationship between Parkinson's disease and FTD-ALS is complex[3]. While these are traditionally considered separate proteinopathies (α-synuclein vs. TDP-43), hybrid cases exist where patients present with both Lewy bodies and TDP-43 inclusions[4]. Clinical features can include:
- Parkinsonian rigidity and bradykinesis with concurrent cognitive decline
- Lewy body dementia with motor neuron signs
- Rapid eye movement sleep behavior disorder as a shared prodromal feature
- Overlapping phenotypes (rigidity, apraxia, alien limb)
- TDP-43 pathology in ~30% of CBD cases
- Shared motor features with ALS
- Common tau pathology in some cases[5]
CBD was originally considered a tauopathy, but approximately 30% of cases show TDP-43 pathology, establishing a link to FTD-ALS[6]. The clinical syndrome includes:
- Asymmetric rigidity and dystonia
- Apraxia (especially limb-kinesthetic)
- Cortical sensory loss
- Alien limb phenomenon
- Cognitive decline meeting FTD criteria in ~30% of cases
The overlap between Huntington's disease and FTD-ALS is rare but documented:
- C9orf72 expansion in some HD families
- CAG repeat length may modify TDP-43 pathology
- Shared mechanism involves RNA toxicity and dipeptide repeat proteins
- Behavioral changes in HD overlap with FTD phenotype[7]
- BAC transgenic models: Express human C9orf72 with expanded repeats
- knock-in models: Human repeat expansion knocked into endogenous mouse locus
- Phenotypes: Cognitive deficits, motor impairment, RNA foci, DPR deposits
- Therapeutic testing: Used for ASO efficacy studies
- Repeat expression models: Hexanucleotide repeat in Drosophila
- Phenotypes: Neurodegeneration, reduced lifespan
- Mechanism studies: RNA foci and DPR toxicity validated
- Patient-derived neurons: Motor neurons from FTD-ALS patient iPSCs
- Phenotypes: RNA foci, DPR production, TDP-43 mislocalization
- Drug screening: Platform for high-throughput screening[8]
- TDP-43 A315T: First ALS-causing mutation identified
- TDP-43 M337V: Common mutation showing progressive phenotype
- Conditional models: Inducible TDP-43 expression for temporal studies
- Progressive motor impairment
- Muscle denervation and atrophy
- Cytoplasmic TDP-43 inclusions
- Premature death
- FUS R521C: Most common pathogenic mutation
- FUS P525L: Associated with early-onset ALS
- Rapid disease progression
- FUS-positive basophilic inclusions
- Stress granule abnormalities
| Finding |
FTD-ALS |
Pure ALS |
Pure FTD |
| Frontotemporal atrophy |
+++ |
+ |
+++ |
| Motor cortex atrophy |
+++ |
+++ |
+ |
| Precentral gyrus |
++ |
+++ |
+ |
| Pallidum/putamen |
++ |
+ |
+ |
| Brainstem |
+ |
+ |
+ |
- Fractional anisotropy reduction in:
- Corpus callosum
- Corticospinal tracts
- Frontotemporal white matter
- Apparent diffusion coefficient increase
- Useful for tracking disease progression
- Default mode network disruption
- Salience network hyperconnectivity (early)
- Motor network hypoconnectivity (progression)
- FDG-PET: Hypometabolism in frontal/temporal regions
- PiB-PET: May show amyloid in FTD-ALS/AD overlap
- TAU-PET: Minimal uptake (distinguishes from AD)
- Short-interval intracortical inhibition (SICI): Reduced
- Motor evoked potential (MEP) amplitude: Increased
- Cortical silent period: Shortened
- Typically normal in pure ALS-FTD
- May show reduced amplitudes in ALS component
- Fibrillation potentials
- Positive sharp waves
- Fasciculation potentials
- Reduced recruitment
| Protein |
Change |
Specificity |
Stage |
| NfL |
3-10x elevation |
Moderate |
All stages |
| pNfH |
2-5x elevation |
High |
Progressive |
| TDP-43 (total) |
Elevated |
Moderate |
Active disease |
| pTDP-43 |
Elevated |
High |
Pathology |
| CHIT1 |
Elevated |
High |
Microglia |
| NFL |
3-10x elevation |
Moderate |
All stages |
- Energy metabolism: Reduced TCA cycle intermediates
- Amino acids: Elevated glutamate, reduced GABA
- Lipids: Altered phospholipid profile
- Nucleotides: Reduced ATP, elevated ADP
- Mechanism: Glutamate release inhibition, sodium channel block
- Dosing: 50mg twice daily
- Efficacy: 2-3 month survival benefit
- Side effects: Nausea, fatigue, liver enzyme elevation
- Mechanism: Free radical scavenger
- Dosing: 60mg IV infusion, 10 days monthly
- Efficacy: Slowed functional decline in early disease
- Side effects: Bruising, gait disturbance, headaches
- SSRIs: Sertraline (25-150mg), citalopram (10-40mg)
- SNRIs: Venlafaxine (75-225mg)
- Atypical antipsychotics: Quetiapine (25-100mg) - Monitor QTc
- Baclofen: Spasticity (10-30mg TID)
- Tizanidine: Spasticity (2-8mg TID)
- Benzodiazepines: Clonazepam (0.5-2mg) - for myoclonus
- Melatonin: 1-10mg bedtime
- Mirtazapine: 15-45mg bedtime
- Low-dose trazodone: 25-100mg bedtime
| Specialist |
Role |
Frequency |
| Neurologist |
Care coordination |
Monthly |
| Pulmonologist |
Respiratory care |
Monthly |
| Gastroenterologist |
Nutrition/PEG |
As needed |
| Psychiatrist |
Behavioral management |
Monthly |
| Physical therapist |
Mobility |
Weekly |
| Occupational therapist |
ADL |
Weekly |
| Speech therapist |
Communication |
Weekly |
| Dietitian |
Nutrition |
Monthly |
| Social worker |
Support services |
Monthly |
| Palliative care |
Quality of life |
As needed |
- Education and training
- Respite care arrangements
- Support groups
- Financial counseling
- Legal planning (advanced directives)
| Category |
Annual Cost (USD) |
| Direct medical |
$50,000-150,000 |
| Direct non-medical |
$20,000-50,000 |
| Informal care |
$30,000-100,000 |
| Productivity loss |
$40,000-80,000 |
| Total |
$140,000-380,000 |
- Hospitalizations
- Assistive devices
- Home modifications
- Caregiver time
- Medications
- Global ALS cases: ~400,000
- Global FTD cases: ~1.2 million
- FTD-ALS overlap: ~50,000-100,000
- Annual deaths (ALS): ~100,000 worldwide
- Specialist workforce development
- Care infrastructure investment
- Research funding priorities
- Drug access policies